In support of this possibility, mutations of IDH1 and IDH2 also occur in myeloid malignancies where neomorphic activity of the enzyme results in aberrant generation of 2-hydroxyglutarate, which inhibits the 2-oxoglutarate dependent conversion of 5mC to 5hmC by TET2 [4, 7]. This evidence concerns the gene IDH1 and myeloid neoplasm.